Cost-utility of oral methylprednisolone in the treatment of multiple sclerosis relapses: Results from the COPOUSEP trial

Autor: Michel, M., Le Page, E., Laplaud, D.A., Wardi, R., Lebrun, C., Zagnoli, F., Wiertlewski, S., Coustans, M., Edan, G., Chevreul, K., Veillard, D., Lallement, F., Cohen, M., Blanchard, C., Sartori, E., Demarco, O., Rouhart, F., Papeix, C., Taurin, G., Anani, T., Kassiotis, P., Hamon, C., Lester, M.A., Merienne, M.
Zdroj: Revue Neurologique; March 2022, Vol. 178 Issue: 3 p241-248, 8p
Abstrakt: •Oral methylprednisolone is cost-effective when administered in the hospital.•When administered at home, it is more effective and less costly.•Its use is associated with millions in cost savings.•It should be widely prescribed to treat multiple sclerosis relapses.
Databáze: Supplemental Index
Externí odkaz: